Eli Lilly and Company (LLY) Stock Price & Analysis
Market: NYSE • Sector: Healthcare • Industry: Drug Manufacturers - General
Eli Lilly and Company (LLY) Profile & Business Summary
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Key Information
| Ticker | LLY |
|---|---|
| Leadership | David A. Ricks |
| Exchange | NYSE |
| Official Site | https://www.lilly.com |
Market Trend Overview for LLY
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
This model looks at how prices behave over time to describe the current market environment. It focuses on whether price is moving steadily, stalling, or losing momentum, and checks both short-term and weekly trends for confirmation. The goal is not to predict exact prices, but to help understand when conditions are supportive, risky, or unclear.
Current Market Context (Short-Term)
As of 2026-02-06 (ET), LLY is moving sideways. Price at 1058.18 is moving between support near 1033.38 and resistance near 1095.48. There is no clear direction right now. View Support & Resistance from Options
Why the market looks this way?
Prices have moved back and forth over recent sessions without making steady progress. Trend signals have changed frequently, which suggests the market is stuck in a range. In this environment, chasing moves in either direction is less reliable.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-02-06 (ET)
As of 2026-02-06, LLY is moving sideways with low volatility. Over the longer term, the trend remains bullish.
LLY last closed at 1058.18. The price is about 0.1 ATR above its recent average price (1056.38), and the market is currently in a sideways market with low volatility.
Price is moving in a tight range. This often leads to a stronger move once the range breaks, increasing one-sided risk.
Trend score: 40 out of 100. Overall alignment is unclear. The market is currently in a sideways phase with tightening price movement. The longer-term trend is still positive, but short-term signals are not yet confirming it.
A key downside level is near 990.82. If price falls below this area, the current upward trend would likely weaken or break.
On 2026-02-03, trend conditions deteriorated, suggesting that moves in the prior direction became less dependable.
[2026-01-12] Price moved quickly and looked strong, but participation was limited.
Recent bars show mixed price behavior without a clear shift in structural quality or efficiency.
Buying into the close appeared steady and controlled, consistent with deliberate overnight positioning.
Short Interest & Covering Risk for LLY
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is relatively low, indicating limited pressure from short positions. (Historical percentile: 34%)
Structure Analysis
LLY Short positioning looks normal. Current days to cover is 2.5 trading days, meaning short positions would unwind somewhat slower than average. Short covering is likely to have a normal impact on price moves.
Bull Trap Structural Risk
No clear bull trap characteristics detected. Recent price behavior remains broadly consistent with current positioning.This reading helps confirm that current price action remains structurally healthy and does not indicate elevated trap risk.
In the latest reporting period, short interest continues to increase. As a result, similar news or market events could lead to price moves about 1× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-01-15 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.